Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myeloid Cell Function and Cytokine Profiles in Paediatric Haemophilia A: Insights From FVIII and Emicizumab Prophylaxis.

Journal of cellular and molecular medicine·2026
Same author

Chaperone-mediated autophagy is a tumor-suppressive mechanism in hepatocellular carcinoma.

Cell reports·2026
Same author

Chaperone-mediated autophagy is required for regulatory T cell function.

Nature communications·2026
Same author

Peptide-mediated inhibition of aberrant chaperone-mediated autophagy in pericytes prevents glioblastoma progression through MAPT/tau secretion.

Autophagy·2026
Same author

Chaperone-mediated autophagy protects against retinal photoreceptor degeneration by modulating proteostasis of glucose metabolism enzymes.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Implantable vascularized endocrine constructs for clinically scalable insulin delivery.

Trends in biotechnology·2026

Related Experiment Video

Updated: Jul 8, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.

Marta Martinez-Vicente1, Zsolt Talloczy, Susmita Kaushik

  • 1Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Yeshiva University, New York, New York 10461, USA.

The Journal of Clinical Investigation
|January 4, 2008
PubMed
Summary

Altered alpha-synuclein degradation is key in Parkinson disease (PD). Dopamine-modified alpha-syn impairs chaperone-mediated autophagy (CMA), potentially explaining dopaminergic neuron loss in PD.

More Related Videos

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Related Experiment Videos

Last Updated: Jul 8, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Altered alpha-synuclein (alpha-syn) degradation is linked to Parkinson disease (PD) pathogenesis.
  • Chaperone-mediated autophagy (CMA) is a selective lysosomal pathway for cytosolic protein degradation.
  • Pathogenic alpha-syn mutants impair lysosomal translocation, hindering their degradation and that of other CMA substrates.

Purpose of the Study:

  • To investigate the impact of alpha-syn posttranslational modifications on its degradation via CMA.
  • To determine if dopamine modification of alpha-syn affects CMA pathway function.
  • To explore the potential role of impaired CMA in the selective degeneration of dopaminergic neurons in PD.

Main Methods:

  • Utilized mouse ventral medial neuron cultures and SH-SY5Y cells.
  • Employed isolated mouse lysosomes for in vitro degradation assays.
  • Assessed the degradation of alpha-syn and other CMA substrates under various conditions, including dopamine modification.

Main Results:

  • Most posttranslational modifications of alpha-syn impair its CMA-mediated degradation without affecting other substrates.
  • Dopamine-modified alpha-syn is poorly degraded by CMA and inhibits the degradation of other CMA substrates.
  • Impaired CMA function increases cellular vulnerability to stressors.

Conclusions:

  • Posttranslational modifications, particularly dopamine modification, of alpha-syn can disrupt CMA-mediated protein degradation.
  • Dopamine-induced autophagic inhibition offers a potential mechanism for the selective vulnerability of dopaminergic neurons in Parkinson disease.